Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics crawled date : 2021 - 09 - 09 save search
Corcept Announces Presentation of Positive Results From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients With Recurrent Platinum-Resistant Ovarian Cancer at ESMO 2021
Published: 2021-09-09 (Crawled : 22:00) - biospace.com/
CORT M | $23.0 -1.67% -1.7% 960K
|
Health Technology
|
| O: 0.05%
H: 0.19%
C: -0.89%
presentation phase 2 positive results positive results cancer ovarian cancer trial
Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform in the American Journal of Rhinology & Allergy
Published: 2021-09-09 (Crawled : 22:00) - biospace.com/
LYRA | $5.405 0.09% 0.09% 300K
|
Health Technology
|
| O: -1.22%
H: 5.31%
C: 3.58%
drug technology preclinical pre-clinical
TScan Therapeutics Appoints Zoran Zdraveski, J.D., Ph.D. as Chief Legal Officer
Published: 2021-09-09 (Crawled : 22:00) - biospace.com/
TCRX | News 0 d | $6.75 -5.33% -5.47% 1.6M
|
Professional, Scientific, and T...
|
| O: 0.58%
H: 0.93%
C: -2.79%
Regulus Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Published: 2021-09-09 (Crawled : 21:00) - prnewswire.com
RGLS | $2.34 -8.59% -9.17% 300K
|
Health Technology
|
| O: -0.11%
H: 4.78%
C: 3.25%
conference
Gain Therapeutics to Present at 2021 International Virtual GM1 Community Conference
Published: 2021-09-09 (Crawled : 21:00) - globenewswire.com
GANX | $3.18 0.63% -0.64% 81K
|
Professional, Scientific, and T...
|
| O: 0.89%
H: 3.74%
C: -0.77%
conference
atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depression
Published: 2021-09-09 (Crawled : 21:00) - globenewswire.com
ATAI | News | $1.98 -7.91% -8.59% 1.4M
|
Manufacturing
|
| O: 1.06%
H: 0.0%
C: -4.02%
treatment test depression life science ketamine
Monopar Therapeutics to Present at Upcoming Investor Conferences in September
Published: 2021-09-09 (Crawled : 19:00) - biospace.com/
MNPR | $0.655 -10.03% -3.57% 150K
|
Health Technology
|
| O: -0.55%
H: 28.55%
C: 10.5%
conference presentation therapeutics
MyMD Pharmaceuticals to Present its Novel Therapeutic Platforms for Extending Healthy Lifespan at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15
Published: 2021-09-09 (Crawled : 19:00) - biospace.com/
MYMD | $2.25 7.14% 0.0% 45K
|
Manufacturing
|
| O: 0.0%
H: 7.19%
C: 3.6%
conference
Tenax Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Published: 2021-09-09 (Crawled : 19:00) - biospace.com/
TENX | $3.59 -0.55% -0.84% 25K
|
Health Technology
|
| O: 2.07%
H: 0.0%
C: -3.04%
conference
Lycia Therapeutics Announces $70 Million Series B Financing Led by Redmile Group with Participation from Founding Investor Versant Ventures
Published: 2021-09-09 (Crawled : 19:00) - biospace.com/
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
|
| O: -0.61%
H: 0.29%
C: -5.25%
RAPT | $8.04 -1.11% -1.5% 630K
|
Health Technology
|
| O: -1.47%
H: 5.72%
C: 1.58%
ADVM | $11.35 -2.24% -2.56% 68K
|
Health Technology
|
| O: -0.07%
H: 3.99%
C: 1.81%
ITERUM THERAPEUTICS (NASDAQ: ITRM) INVESTOR FILING DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Has Been Filed Against Iterum Therapeutics plc
Published: 2021-09-09 (Crawled : 19:00) - prnewswire.com
ITRM | $1.46 0.69% -2.11% 76K
|
Health Technology
|
| O: -1.56%
H: 1.6%
C: -1.19%
Orchard Therapeutics Bolsters R&D and Technical Operations Leadership with New Executive Appointments
Published: 2021-09-09 (Crawled : 19:00) - biospace.com/
ORTX | $16.7 0.0% 370K
|
Health Technology
|
| O: -0.69%
H: 6.6%
C: 0.35%
BIIB | $192.16 -1.53% -1.57% 1.1M
|
Health Technology
|
| O: 0.14%
H: 0.15%
C: -6.79%
AKBA | $1.39 -0.71% -0.72% 2.8M
|
Health Technology
|
| O: 1.02%
H: 2.86%
C: -0.67%
Rani Therapeutics Announces Appointment of Eric Groen as General Counsel
Published: 2021-09-09 (Crawled : 19:00) - biospace.com/
RANI | $7.85 14.27% 11.58% 1.4M
|
|
| O: -1.45%
H: 13.1%
C: 2.89%
therapeutics
Medicenna Therapeutics to Present at Upcoming September Investor Conferences
Published: 2021-09-09 (Crawled : 18:00) - biospace.com/
MDNA | $0.157 -0.32% 1.3M
|
Health Technology
|
| O: -0.78%
H: 5.49%
C: 1.57%
conference presentation therapeutics
Freeline Announces Orphan Drug Designations for FLT201 for the Treatment of Gaucher DiseaseClinical trial site initiation for Gaucher disease Type 1 on track by year end
Published: 2021-09-09 (Crawled : 15:00) - biospace.com/
FRLN | $6.48 0.0% 0
|
Health Technology
|
| O: 0.0%
H: 1.61%
C: -0.25%
disease treatment orphan drug drug trial pons designation
Denali Therapeutics Announces Initiation of Phase 1b Study of EIF2B Activator DNL343 in ALS— Investigational EIF2B activator approach has potential to be a first-in-class treatment for ALS —
Published: 2021-09-09 (Crawled : 14:00) - biospace.com/
DNLI | $16.82 -3.0% -3.15% 960K
|
Health Technology
|
| O: -0.11%
H: 2.54%
C: -0.3%
treatment phase 1 potential phase 1b als phase 2b
Nabriva and Vizient Enter into Agreement to Make XENLETA® (lefamulin) Available to Vizient’s Pharmacy Network Program
Published: 2021-09-09 (Crawled : 13:00) - globenewswire.com
NBRV | $1.42 1.39% 720K
|
Health Technology
|
| O: 2.68%
H: 0.87%
C: -2.61%
lefamulin
Aldeyra Therapeutics to Participate in the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Published: 2021-09-09 (Crawled : 13:00) - biospace.com/
ALDX 4 | $3.97 2.58% 2.76% 600K
|
Health Technology
|
| O: -0.11%
H: 0.9%
C: 0.0%
life science
Decibel Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations for DB-OTO for the Treatment of Otoferlin-Related Congenital Hearing Loss
Published: 2021-09-09 (Crawled : 13:00) - biospace.com/
DBTX | $4.91 -0.81% -0.2% 0
|
Health Technology
|
| O: 4.66%
H: 3.72%
C: -2.85%
disease treatment rare pediatric disease designation orphan drug drug hearing loss designation rare
Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration
Published: 2021-09-09 (Crawled : 13:00) - biospace.com/
TWST | $28.57 -0.14% -0.25% 840K
|
Health Technology
|
| O: 0.26%
H: 7.79%
C: 5.95%
collaboration antibody therapeutics bioscience
Gainers vs Losers
| 57% | 43% |
Top 10 Gainers
INVO | $1.82 139.47% 56.82% 220M
|
Health Technology
SINT | $0.0373 62.88% 37.26% 460M
|
Health Technology
WISA 4 | $9.25 51.64% 34.27% 64M
|
Electronic Technology
EDBL | News | $6.66 46.37% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 600K
|
Manufacturing
TCON | $2.29 33.92% 26.61% 1.8M
|
Health Technology
TIRX | $0.4848 7.49% 24.58% 5.9M
|
SRFM 4 | $0.3859 -12.3% 23.84% 660K
|
n/a
KZIA | $0.3442 18.28% 23.42% 290K
|
Health Technology
CTM | $0.2201 -2.31% 22.67% 48K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.